https://www.thebodypro.com/category/adverse-events-comorbidities-hiv/tag/tuberculosis

The Latest

global COVID-19 mask

Joint Action and Service Integration Needed to Tackle HIV and TB During COVID-19 Pandemic, Experts Agree

Global health leaders warn that the pandemic may impact health systems and worsen the world's pre-existing epidemics.

By Barbara Jungwirth
The Opioid Epidemic Is Fueling HIV Cluster Outbreaks -- Here's How the CDC is Responding Img

The Opioid Epidemic Is Fueling HIV Cluster Outbreaks -- Here's How the CDC is Responding

Epidemiologists are using a combination of molecular surveillance and tuberculosis-style contact tracing in hopes of helping local health departments curb HIV transmissions.

By Sony Salzman
TB Causes 1 in 3 HIV Deaths Img

TB Causes 1 in 3 HIV Deaths

In 2017, 300,000 of the total 940,000 global HIV deaths occurred among people infected by both HIV and tuberculosis (TB), according to the WHO "Global TB report 2018" launched last week.

By World Health Organization
Dual Therapy Can Reduce TB Prophylaxis From Nine Months to One: Fewer Side Effects and More People Complete Treatment Img

Dual Therapy Can Reduce TB Prophylaxis From Nine Months to One: Fewer Side Effects and More People Complete Treatment

New results presented at CROI 2018 from a large international study using a simplified approach to prevent TB have the potential to dramatically improve outcomes for HIV positive people.

By Simon Collins for HIV i-Base
Twice-Daily Dolutegravir Is Effective and Tolerable With Rifampicin Img

Twice-Daily Dolutegravir Is Effective and Tolerable With Rifampicin

24-week interim results from the INSPIRING study presented at CROI 2018 show that dolutegravir 50 mg twice daily is effective and well-tolerated in adults with HIV/TB receiving rifampicin-based TB treatment.

By Polly Clayden for HIV i-Base
Once-Daily Tenofovir Alafenamide Appears Sufficient When Dosed With Rifampicin Img

Once-Daily Tenofovir Alafenamide Appears Sufficient When Dosed With Rifampicin

A review of the effect of rifampin on tenofovir alafenamide (TAF) plasma/intracellular pharmacokinetics presented at CROI 2018.

By Polly Clayden for HIV i-Base
Significant Drug-Drug Interaction Between Dolutegravir and Isoniazid-Rifapentine Img

Significant Drug-Drug Interaction Between Dolutegravir and Isoniazid-Rifapentine

Dolutegravir (Tivicay) given with once-weekly isoniazid-rifapentine led to marked cytokine release and serious adverse events in a drug-drug interaction study.

By Polly Clayden for HIV i-Base
Twice-Daily Tenofovir Alafenamide Dose Might Overcome Interaction With Rifampicin Img

Twice-Daily Tenofovir Alafenamide Dose Might Overcome Interaction With Rifampicin

Twice-daily tenofovir alafenamide plus rifampicin provided similar exposures to once-daily TAF in a pharmacokinetic study. This strategy might be a suitable option for people with HIV/TB coinfection.

By Polly Clayden for HIV i-Base
Dolutegravir-Based ART in Combination With Rifampicin-Based TB Treatment Is Safe in a Small Cohort of Co-Infected Patients Img

Dolutegravir-Based ART in Combination With Rifampicin-Based TB Treatment Is Safe in a Small Cohort of Co-Infected Patients

Twice daily dolutegravir in combination with rifampicin was well tolerated and produced good outcomes in a small retrospective study presented at HIV Drug Therapy Glasgow 2016.

By Polly Clayden for HIV i-Base
These foods all contain vitamin D. (Credit: Shutterstock)

Why Taking Vitamin D Pills Could Help the Fight Against TB and HIV

In countries such as South Africa with a high burden of TB and HIV, vitamin D could be an extremely effective and cheap weapon to include in the arsenal against the diseases.

By Anna Coussens and Allison Seeger for The Conversation